$KNSA
Kiniksa Pharmaceuticals Ltd

2022 Q2 Form 10-Q Financial Statement

#000155837022012203 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $26.97M $32.19M $18.75M
YoY Change 250.1%
Cost Of Revenue $5.029M $4.219M $3.867M
YoY Change 103.93%
Gross Profit $21.94M $27.97M $14.88M
YoY Change 318.92%
Gross Profit Margin 81.35% 86.89% 79.37%
Selling, General & Admin $23.84M $22.22M $22.74M
YoY Change 9.12% 7.85% 46.72%
% of Gross Profit 108.65% 79.44% 152.85%
Research & Development $13.80M $20.82M $27.43M
YoY Change -42.38% -27.42% -26.65%
% of Gross Profit 62.88% 74.43% 184.39%
Depreciation & Amortization $350.0K $359.0K $668.0K
YoY Change -15.87% 23.79% 17.19%
% of Gross Profit 1.6% 1.28% 4.49%
Operating Expenses $37.64M $43.04M $51.01M
YoY Change -17.81% -12.68% -3.57%
Operating Profit -$19.37M -$23.32M -$36.13M
YoY Change -52.24% -52.68%
Interest Expense $103.0K $34.00K $77.00K
YoY Change 1616.67% 240.0% 156.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$19.27M -$23.29M -$36.05M
YoY Change -52.49% -52.74% -31.81%
Income Tax $716.0K $1.925M $279.0K
% Of Pretax Income
Net Earnings -$19.98M -$25.21M -$36.33M
YoY Change -51.93% -49.05% -32.29%
Net Earnings / Revenue -74.08% -78.32% -193.83%
Basic Earnings Per Share -$0.29 -$0.36
Diluted Earnings Per Share -$0.29 -$0.36 -$526.8K
COMMON SHARES
Basic Shares Outstanding 69.29M 69.14M
Diluted Shares Outstanding 69.29M 69.14M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $138.2M $145.6M $182.2M
YoY Change -38.81% -44.86% -43.68%
Cash & Equivalents $94.31M $63.32M $122.5M
Short-Term Investments $43.90M $82.25M $59.73M
Other Short-Term Assets $14.01M $10.52M $6.585M
YoY Change 39.89% 13.09% -32.81%
Inventory $19.92M $13.22M $3.675M
Prepaid Expenses
Receivables $7.808M $29.44M $3.985M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $179.9M $198.8M $196.4M
YoY Change -26.5% -27.87% -41.05%
LONG-TERM ASSETS
Property, Plant & Equipment $2.150M $2.475M $2.834M
YoY Change -37.66% -35.12% -30.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.669M $5.918M $8.720M
YoY Change -2.48% 2.09% 56.05%
Total Long-Term Assets $30.64M $32.21M $36.35M
YoY Change -10.93% -9.51% 124.2%
TOTAL ASSETS
Total Short-Term Assets $179.9M $198.8M $196.4M
Total Long-Term Assets $30.64M $32.21M $36.35M
Total Assets $210.6M $231.0M $232.8M
YoY Change -24.58% -25.77% -33.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.522M $3.383M $1.868M
YoY Change -39.32% 22.44% 271.37%
Accrued Expenses $34.50M $38.89M $38.03M
YoY Change 11.06% 28.27% 30.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.54M $50.35M $44.82M
YoY Change 12.28% 42.03% 40.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $260.0K $271.0K $270.0K
YoY Change -77.21% -66.5% -66.46%
Total Long-Term Liabilities $260.0K $271.0K $270.0K
YoY Change -77.21% -66.5% -66.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.54M $50.35M $44.82M
Total Long-Term Liabilities $260.0K $271.0K $270.0K
Total Liabilities $57.08M $64.72M $47.76M
YoY Change 31.46% 59.96% 27.27%
SHAREHOLDERS EQUITY
Retained Earnings -$720.6M -$700.6M -$675.4M
YoY Change 18.42% 23.57% 30.52%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $153.5M $166.2M $185.0M
YoY Change
Total Liabilities & Shareholders Equity $210.6M $231.0M $232.8M
YoY Change -24.58% -25.77% -33.38%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$19.98M -$25.21M -$36.33M
YoY Change -51.93% -49.05% -32.29%
Depreciation, Depletion And Amortization $350.0K $359.0K $668.0K
YoY Change -15.87% 23.79% 17.19%
Cash From Operating Activities -$7.824M -$36.85M -$18.88M
YoY Change -79.83% -8.17% -54.15%
INVESTING ACTIVITIES
Capital Expenditures -$115.0K $0.00 -$251.0K
YoY Change 82.54% -100.0% 402.0%
Acquisitions
YoY Change
Other Investing Activities $38.38M -$22.72M -$49.79M
YoY Change -55.4% -135.02% -172.47%
Cash From Investing Activities $38.27M -$22.72M -$50.04M
YoY Change -55.5% -150.68% -172.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 542.0K 423.0K 1.212M
YoY Change -38.62% -61.75% 68.33%
NET CHANGE
Cash From Operating Activities -7.824M -36.85M -18.88M
Cash From Investing Activities 38.27M -22.72M -50.04M
Cash From Financing Activities 542.0K 423.0K 1.212M
Net Change In Cash 30.98M -59.15M -67.71M
YoY Change -35.58% -1116.6% -340.29%
FREE CASH FLOW
Cash From Operating Activities -$7.824M -$36.85M -$18.88M
Capital Expenditures -$115.0K $0.00 -$251.0K
Free Cash Flow -$7.709M -$36.85M -$18.63M
YoY Change -80.09% -8.29% -54.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69289972
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68395703
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69213860
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68332943
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94307000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
122470000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
43901000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
59731000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7808000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3985000
CY2022Q2 us-gaap Inventory Net
InventoryNet
19916000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3675000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14006000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6585000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
179938000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
196446000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2150000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2834000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4069000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5550000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
dei Entity Central Index Key
EntityCentralIndexKey
0001730430
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-24000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
61000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5669000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8720000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69289972
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68395703
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69213860
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68332943
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
dei Document Quarterly Report
DocumentQuarterlyReport
true
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42550000
dei Entity Address City Or Town
EntityAddressCityOrTown
Hamilton
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
HM11
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38492
dei Entity Registrant Name
EntityRegistrantName
Kiniksa Pharmaceuticals, Ltd.
dei Entity Address Country
EntityAddressCountry
BM
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
D0
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1327726
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
dei Entity Address Address Line1
EntityAddressAddressLine1
Clarendon House
dei Entity Address Address Line2
EntityAddressAddressLine2
2 Church Street
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q4 us-gaap Liabilities
Liabilities
47763000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
874153000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
860482000
dei City Area Code
CityAreaCode
808
dei Local Phone Number
LocalPhoneNumber
451-3453
dei Security12b Title
Security12bTitle
Class A Common Shares
dei Trading Symbol
TradingSymbol
KNSA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18750000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19250000
CY2022Q2 us-gaap Assets
Assets
210576000
CY2021Q4 us-gaap Assets
Assets
232800000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2522000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1868000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34500000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38031000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3336000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3381000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3186000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1544000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
43544000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44824000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1278000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2669000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12000000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
260000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
270000
CY2022Q2 us-gaap Liabilities
Liabilities
57082000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19265000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40549000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-90000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-66000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-720588000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-675397000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
153494000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185037000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
210576000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
232800000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26972000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7704000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59161000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7704000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13798000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23945000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34615000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52628000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23841000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21848000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46059000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42448000
CY2022Q2 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
46340000
CY2021Q2 knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
48259000
knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
101848000
knsa Total Cost Of Revenue And Operating Expenses
TotalCostOfRevenueAndOperatingExpenses
97542000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-19368000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-40555000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42687000
us-gaap Operating Income Loss
OperatingIncomeLoss
-89838000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
103000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000
us-gaap Investment Income Interest
InvestmentIncomeInterest
137000
us-gaap Investment Income Interest
InvestmentIncomeInterest
15000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-89823000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
716000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1014000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2641000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1224000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19981000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
us-gaap Net Income Loss
NetIncomeLoss
-45191000
us-gaap Net Income Loss
NetIncomeLoss
-91047000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69289972
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68395703
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69213860
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68332943
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19981000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
us-gaap Net Income Loss
NetIncomeLoss
-45191000
us-gaap Net Income Loss
NetIncomeLoss
-91047000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3293000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
654000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3654000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
48000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-24000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
61000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19968000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41515000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45215000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-90986000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185037000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
423000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6031000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-37000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25210000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166244000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
542000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6676000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19981000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
153494000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
311935000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1106000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7126000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-49484000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
270696000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
887000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5717000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
235785000
us-gaap Profit Loss
ProfitLoss
-45191000
us-gaap Profit Loss
ProfitLoss
-91047000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1307000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1029000
us-gaap Share Based Compensation
ShareBasedCompensation
12707000
us-gaap Share Based Compensation
ShareBasedCompensation
12843000
knsa Noncash Lease Expense
NoncashLeaseExpense
1481000
knsa Noncash Lease Expense
NoncashLeaseExpense
1193000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-240000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-603000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-34000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7421000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
196000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3823000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2551000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
16241000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6381000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-2918000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
279000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122470000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114248000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1889000
CY2022Q2 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
2769000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94307000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
168163000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2753000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1436000
knsa Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-863000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
12000000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-10000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
337000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44670000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78905000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
91000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
55734000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
97460000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
71300000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
248400000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
20000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15542000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
130827000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1558000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1993000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
593000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
965000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1993000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28163000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
53915000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the recognition of revenue, the capitalization of inventory, the accrual for research and development expenses and the valuation of share-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p>
CY2022Q2 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
2769000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-720588000
us-gaap Net Income Loss
NetIncomeLoss
-45191000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44670000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
138208000
CY2022Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
knsa Number Of Securities Unrealized Loss Position
NumberOfSecuritiesUnrealizedLossPosition
14
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
43901000
CY2021 knsa Number Of Securities Unrealized Loss Position
NumberOfSecuritiesUnrealizedLossPosition
11
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
49739000
CY2022Q2 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
1262000
CY2022Q2 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
1271000
CY2022Q2 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
236000
CY2021Q4 knsa Product Revenue Reserve For Contractual Adjustments
ProductRevenueReserveForContractualAdjustments
515000
CY2021Q4 knsa Product Revenue Reserve For Government Rebates
ProductRevenueReserveForGovernmentRebates
719000
CY2021Q4 knsa Product Revenue Reserve For Sales Returns
ProductRevenueReserveForSalesReturns
101000
CY2021Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
1335000
knsa Product Revenue Provision For Contractual Adjustments
ProductRevenueProvisionForContractualAdjustments
3303000
knsa Product Revenue Provision For Government Rebates
ProductRevenueProvisionForGovernmentRebates
1621000
knsa Product Revenue Provision For Product Returns
ProductRevenueProvisionForProductReturns
135000
knsa Product Revenue Provision For Reserves And Allowances
ProductRevenueProvisionForReservesAndAllowances
5059000
knsa Product Revenue Refunds On Contractual Adjustments
ProductRevenueRefundsOnContractualAdjustments
2255000
knsa Product Revenue Refunds And Payments On Government Rebates
ProductRevenueRefundsAndPaymentsOnGovernmentRebates
448000
knsa Product Revenue Refunds And Credits For Reserves And Allowances
ProductRevenueRefundsAndCreditsForReservesAndAllowances
2703000
knsa Product Revenue Contractual Adjustments Payments And Sales Returns Prior Year Sales
ProductRevenueContractualAdjustmentsPaymentsAndSalesReturnsPriorYearSales
301000
knsa Product Revenue Government Rebates Payments And Sales Returns Prior Year Sales
ProductRevenueGovernmentRebatesPaymentsAndSalesReturnsPriorYearSales
621000
knsa Product Revenue Refunds And Credits For Reserves And Allowances Prior Year Sales
ProductRevenueRefundsAndCreditsForReservesAndAllowancesPriorYearSales
922000
CY2021Q4 knsa Product Revenue Reserves And Allowances
ProductRevenueReservesAndAllowances
1335000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
19916000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3675000
CY2022Q2 us-gaap Inventory Net
InventoryNet
19916000
CY2021Q4 us-gaap Inventory Net
InventoryNet
3675000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2150000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2834000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8579000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8749000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6429000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5915000
CY2022Q2 us-gaap Depreciation
Depreciation
350000
CY2021Q2 us-gaap Depreciation
Depreciation
416000
us-gaap Depreciation
Depreciation
709000
us-gaap Depreciation
Depreciation
706000
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20000000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1250000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18750000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
20000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
750000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19250000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69213860
CY2022Q2 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
14374000
CY2021Q4 knsa Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
24977000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7410000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8916000
CY2022Q2 knsa Accrued Collaboration Expenses Current
AccruedCollaborationExpensesCurrent
9612000
CY2021Q4 knsa Accrued Collaboration Expenses Current
AccruedCollaborationExpensesCurrent
835000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2734000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2933000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
370000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
370000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34500000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38031000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68332943
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6676000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5717000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12707000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12843000
knsa Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
12000000
CY2022Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12000000
CY2017Q3 knsa Time Period To Terminate Agreement By Both Parties Under Uncured Material Breaches
TimePeriodToTerminateAgreementByBothPartiesUnderUncuredMaterialBreaches
P90D
CY2017Q3 knsa Time Period To Terminate Agreement Under Payment Related Breaches
TimePeriodToTerminateAgreementUnderPaymentRelatedBreaches
P30D
CY2017Q3 knsa Consecutive Suspension Of Activities Period To Terminate Agreement
ConsecutiveSuspensionOfActivitiesPeriodToTerminateAgreement
P12M
CY2017Q3 knsa Time Period To Terminate Agreement After Eighteen Months Of Agreement
TimePeriodToTerminateAgreementAfterEighteenMonthsOfAgreement
P1Y
CY2017Q3 knsa Time Period To Terminate Agreement If Products Are Determined To Have Certain Safety Concerns
TimePeriodToTerminateAgreementIfProductsAreDeterminedToHaveCertainSafetyConcerns
P3M
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69289972
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68395703
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19981000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41563000
us-gaap Net Income Loss
NetIncomeLoss
-45191000
us-gaap Net Income Loss
NetIncomeLoss
-91047000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10732287
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9944017
CY2021Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
CY2022Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
716000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2641000
CY2022Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
37211000

Files In Submission

Name View Source Status
0001558370-22-012203-index-headers.html Edgar Link pending
0001558370-22-012203-index.html Edgar Link pending
0001558370-22-012203.txt Edgar Link pending
0001558370-22-012203-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
knsa-20220630.xsd Edgar Link pending
knsa-20220630x10q.htm Edgar Link pending
knsa-20220630x10q_htm.xml Edgar Link completed
knsa-20220630xex31d1.htm Edgar Link pending
knsa-20220630xex31d2.htm Edgar Link pending
knsa-20220630xex32d1.htm Edgar Link pending
knsa-20220630xex32d2.htm Edgar Link pending
knsa-20220630_cal.xml Edgar Link unprocessable
knsa-20220630_def.xml Edgar Link unprocessable
knsa-20220630_lab.xml Edgar Link unprocessable
knsa-20220630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending